Trading Tips Blog

Jim Cramer, the well-known host of CNBC's "Mad Money," recently shared his thoughts on 12 stocks that have been making headlines. As a retail investor, it's important to pay attention to what experts like Cramer are saying about the market. So, let's take a look at the stocks he's been talking about and what it means for your portfolio. First on the list is Apple (AAPL), a company that needs no introduction. Cramer believes that Apple's recent dip in stock price ...
Read More About This

Cryptocurrency exchange platform Coinbase Global (COIN) saw a sharp decline in its stock price yesterday, dropping over 6% in a single day. This sudden crash was largely due to a sell-off in the overall crypto market, as Bitcoin and other major cryptocurrencies also experienced significant drops. So, what does this mean for retail investors? First, it's important to understand that Coinbase's stock is highly correlated with the performance of the crypto market. As the leading platform for buying and selling cryptocurrencies, ...
Read More About This

Fossil Group, Inc. (NASDAQ:FOSL) recently held its Q1 2025 earnings call, and there were some key takeaways for investors to pay attention to. First and foremost, Fossil reported a strong quarter, with a 10% increase in net sales and a 20% increase in e-commerce sales. This is a positive sign for the company, especially in the current retail landscape. One of the most interesting points from the call was Fossil's focus on its direct-to-consumer business. The company saw a 60% increase in ...
Read More About This

While investors are getting bullish again, the big tech trend is AI. Companies are even mentioning AI more often in their earnings reports than tariffs. That’s good news for growth investors. For investors who are already in on the AI space or are looking for another high-growth trend, good news. Other tech spaces continue to look strong, and many of them carry companies with higher growth profiles than AI plays right now. That includes the growth of commercial space technology. In less ...
Read More About This

Karen Boone, a director at CoreWeave (CRWV), recently bought 10,520 shares. The buy increased her stake by a massive 609%, and came to a total cost of $500,336. This is the first insider buy since last November, when another director bought 423,020 shares for just under $20 million. Otherwise, company insiders have been big sellers of shares around current prices, including a sales from both the company CEO and Chief Strategy Officer for more than half their holdings. Overall, CoreWeave insiders ...
Read More About This

Modular nuclear reactor designer and manufacturer NuScale Power (SMR) is up 210% over the past year. One trader sees shares pulling back in the weeks ahead. That’s based on the June 20 $18 puts. The options have 35 days until expiration, and 8,319 contracts just traded compared to a prior open interest of 203, for a 41-fold rise in volume on the trade. The buyer of the puts paid $0.60 to make the bearish bet. NuScale Power shares recently traded near $23, ...
Read More About This

Investing in artificial intelligence (AI) has been a hot topic in the financial world, and it seems like Meta Platforms CEO Mark Zuckerberg is reaping the rewards. According to prominent tech analyst Gene Munster, Zuckerberg is on "Cloud9" as his company's investments in AI are paying off. Munster, known for his spot-on predictions in the tech industry, believes that Meta Platforms (formerly known as Facebook) is leading the way in AI advancements. He notes that the company's AI technology is not ...
Read More About This

Teva Pharmaceutical Industries Limited (TEVA) has been a hot topic among investors recently, and for good reason. The company's stock has seen a significant increase in value over the past few months, leading many to wonder if this trend will continue. So, what's the bull case for TEVA? First and foremost, TEVA has been making some strategic moves that are paying off. The company has been working to streamline its business, cutting costs and focusing on its core generic drug portfolio ...
Read More About This